11/19
08:30 am
wgs
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
Low
Report
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
11/18
08:30 am
wgs
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
Medium
Report
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
11/16
05:07 am
wgs
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year [Yahoo! Finance]
Medium
Report
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year [Yahoo! Finance]
11/7
04:35 pm
wgs
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
Medium
Report
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
11/4
04:35 pm
wgs
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
Low
Report
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
10/30
01:03 pm
wgs
GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $54.00 to $70.00. They now have a "neutral" rating on the stock.
Low
Report
GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $54.00 to $70.00. They now have a "neutral" rating on the stock.
10/30
11:28 am
wgs
GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at Wells Fargo & Company from $34.00 to $75.00. They now have an "equal weight" rating on the stock.
Low
Report
GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at Wells Fargo & Company from $34.00 to $75.00. They now have an "equal weight" rating on the stock.
10/30
10:08 am
wgs
GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at Craig Hallum from $70.00 to $95.00. They now have a "buy" rating on the stock.
Low
Report
GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at Craig Hallum from $70.00 to $95.00. They now have a "buy" rating on the stock.
10/29
08:00 am
wgs
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
High
Report
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
10/24
02:19 pm
wgs
GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at Craig Hallum from $46.00 to $70.00. They now have a "buy" rating on the stock.
Low
Report
GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at Craig Hallum from $46.00 to $70.00. They now have a "buy" rating on the stock.
10/24
11:10 am
wgs
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
Medium
Report
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
10/16
09:40 am
wgs
GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $32.00 to $54.00. They now have a "neutral" rating on the stock.
Low
Report
GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $32.00 to $54.00. They now have a "neutral" rating on the stock.
10/8
08:30 am
wgs
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
Medium
Report
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
10/3
04:05 pm
wgs
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
Medium
Report
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
9/27
04:05 pm
wgs
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/27
06:30 pm
wgs
GeneDx Holdings Corp. (NASDAQ: WGS) is now covered by analysts at Wells Fargo & Company. They set an "equal weight" rating and a $34.00 price target on the stock.
Medium
Report
GeneDx Holdings Corp. (NASDAQ: WGS) is now covered by analysts at Wells Fargo & Company. They set an "equal weight" rating and a $34.00 price target on the stock.